You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas: Inflammatory Diseases
Janssen Receives CHMP Positive Opinion for Expanded Use of Tremfya in the Treatment of Active Psoriatic Arthritis in the European Union
21 October 2020 - - The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the expanded use of Tremfya (guselkumab) for the treatment of adult patients with active psoriatic arthritis in the European Union, US-based healthcare company Johnson and Johnson's (NYSE: JNJ) The Janssen Pharmaceutical Companies business said.
Guselkumab is currently approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Guselkumab is a monoclonal antibody that selectively binds to the p19 subunit of interleukin -23 and inhibits its interaction with the IL-23 receptor.
IL-23 is an important driver in the pathogenesis of inflammatory diseases such as PsA, psoriasis and others.
PsA is a chronic, immune-mediated, inflammatory disease that is progressive and is characterised by debilitating joint damage and inflammation, in addition to enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis.
There is no known cure, and it is estimated that up to a third of the 14 m people who are living with psoriasis in Europe will also go on to develop PsA.
The CHMP positive opinion is based on data from DISCOVER-1 and DISCOVER-2, two first-in-class Phase 3 clinical studies, that demonstrated the efficacy and safety of guselkumab 100 mg q4w and q8w for the treatment of active PsA in adult patients. Data from these studies were recently published in The Lancet in March 2020.
DISCOVER-1 evaluated 381 participants with active PsA who had an inadequate response to standard therapies, including participants previously treated with anti-tumour necrosis factor alpha biologics.6 DISCOVER-2 included 739 patients who were biologic-naïve only and had an inadequate response to standard therapies.
Results published in The Lancet showed that in both studies, at week 24, the primary endpoints of American College of Rheumatology 20 % improvement (ACR20) achieved statistical significance (DISCOVER-1: p
Guselkumab is currently approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Guselkumab is a monoclonal antibody that selectively binds to the p19 subunit of interleukin -23 and inhibits its interaction with the IL-23 receptor.
IL-23 is an important driver in the pathogenesis of inflammatory diseases such as PsA, psoriasis and others.
PsA is a chronic, immune-mediated, inflammatory disease that is progressive and is characterised by debilitating joint damage and inflammation, in addition to enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis.
There is no known cure, and it is estimated that up to a third of the 14 m people who are living with psoriasis in Europe will also go on to develop PsA.
The CHMP positive opinion is based on data from DISCOVER-1 and DISCOVER-2, two first-in-class Phase 3 clinical studies, that demonstrated the efficacy and safety of guselkumab 100 mg q4w and q8w for the treatment of active PsA in adult patients. Data from these studies were recently published in The Lancet in March 2020.
DISCOVER-1 evaluated 381 participants with active PsA who had an inadequate response to standard therapies, including participants previously treated with anti-tumour necrosis factor alpha biologics.6 DISCOVER-2 included 739 patients who were biologic-naïve only and had an inadequate response to standard therapies.
Results published in The Lancet showed that in both studies, at week 24, the primary endpoints of American College of Rheumatology 20 % improvement (ACR20) achieved statistical significance (DISCOVER-1: p
Login
Related Headlines
FairJourney Biologics Enters Antibody Discovery Pact with Pandion Therapeutics
RedHill Biopharma collaborates with two US-based manufacturers for large-scale Opaganib production
Vedanta Biosciences Names Karuna Therapeutics CFO Ignelzi to Its Board of Directors
FDA Grants Emergency Use Authorisation for Baricitinib in Hospitalised COVID-19